JP2004189685A - Functional composition for oral administration - Google Patents

Functional composition for oral administration Download PDF

Info

Publication number
JP2004189685A
JP2004189685A JP2002361581A JP2002361581A JP2004189685A JP 2004189685 A JP2004189685 A JP 2004189685A JP 2002361581 A JP2002361581 A JP 2002361581A JP 2002361581 A JP2002361581 A JP 2002361581A JP 2004189685 A JP2004189685 A JP 2004189685A
Authority
JP
Japan
Prior art keywords
glucosamine
mucopolysaccharide
taurine
weight
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002361581A
Other languages
Japanese (ja)
Inventor
Keijiro Uchino
敬二郎 内野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KYOTO EIYO KAGAKU KENKYUSHO KK
NIPPN Corp
Original Assignee
KYOTO EIYO KAGAKU KENKYUSHO KK
Nippon Flour Mills Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KYOTO EIYO KAGAKU KENKYUSHO KK, Nippon Flour Mills Co Ltd filed Critical KYOTO EIYO KAGAKU KENKYUSHO KK
Priority to JP2002361581A priority Critical patent/JP2004189685A/en
Publication of JP2004189685A publication Critical patent/JP2004189685A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a functional composition for oral administration, effective for the restoration of abraded cartilage, the lessening of pain and the reduction of stress caused by arthralgia to assure a comfortable life with quiet and deep sleep, giving comprehensive satisfaction and common sensation, having quick action and takable as a food. <P>SOLUTION: The functional composition for oral administration contains 0.01-100 pts. wt. of taurine and/or 0.01-100 pts. wt. of γ-aminobutyric acid per 100 pts. wt. of glucosamine or its edible salt. More preferably, the functional composition further contains 0.5-1,500 pts. wt. of at least one kind of component selected from mucopolysaccharide, mucopolysaccharide complex and mucopolysaccharide protein complex and 0.5-500 pts. wt. of a salicin-containing vegetable extract. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は、食品用形態で摂取することができ、関節炎等に伴う痛みを抑制または改善する機能を有する機能性経口組成物に関するものである。
【0002】
【従来の技術】
現代社会においては、高齢化の進行に伴い、成人病と同時に関節痛で困っている人が急増している。この関節痛は、関節のクッションの役割を果たしている軟骨が消耗し、骨同士が接触することにより、関節に痛みを感じるものである。そのため、関節痛を改善、治療する方法として、関節や軟骨の構成成分であるグルコサミンやコンドロイチン硫酸を補給する方法が広く利用されている。
【0003】
前記グルコサミンは、蟹や海老の甲羅に含まれるキチンより得られる物質で、骨、軟骨、皮膚などの組織を形成するムコ多糖体の構成成分であり、米国やヨーロッパを中心に変形性関節症に対する治療効果が注目され、臨床試験が多数報告されている。一方、前記コンドロイチン硫酸は、動植物の軟骨や粘膜などに多く含まれるムコ多糖類で、軟骨の衝撃吸収性、耐久性を改善する働きがある。
【0004】
前記グルコサミンとコンドロイチン硫酸は、それぞれ別々の経路で軟骨の形成を促進し、健康な関節の維持に有効な素材として知られており、特に両者を併用すると優れた治療効果が得られることが既に開示されている(例えば、特許文献1参照。)。また、グルコサミン及びコンドロイチン硫酸に、更にサリシン含有植物性抽出物(セイヨウシロヤナギの抽出物)を含有することで、食品レベルで摂取可能で、関節炎等の痛みを抑制又は改善し、また関節炎を治療する方向に導く食品用組成物も開示されている(特許文献2参照。)。
【0005】
【特許文献1】
特許第2971579号公報
【特許文献2】
特開2001−314173号公報
【0006】
【発明が解決しようとする課題】
しかしながら、上記のような従来における関節炎に対する改善、治療方法は、前記グルコサミン或いはコンドロイチン硫酸などのムコ多糖の軟骨形成機能による、磨り減った軟骨の修復や痛みの軽減に主眼が置かれているため、関節炎に悩む人々への総合的な満足度、体感度という点でも不十分であり、また速効性に乏しくものであった。ここでいう総合的な満足度、体感度とは、関節炎による関節の痛みの軽減に加え、関節炎によるストレスが軽減され、安眠・熟眠ができ、快適な生活ができるということである。
【0007】
本発明は、上記のような従来の関節炎などによる関節痛への対処方法における問題点に鑑み、単に磨り減った軟骨の修復や痛みの軽減のみでなく、関節痛によるストレスが軽減され、安眠・熟眠ができ、快適な生活ができるという、総合的な満足度、体感度が得られ、しかも速効性があり、かつ食品として摂取可能な機能性経口組成物を提供せんとするものである。
【0008】
【課題を解決するための手段】
本発明者は、関節痛で悩んでいる人々が、単に関節の痛みが緩和されるのみでなく、総合的な満足度、体感度を得られる方法について鋭意研究を重ねた結果、関節炎等に伴う痛みを抑制又は緩和する効果が知られているグルコサミンやコンドロイチン硫酸などのムコ多糖と、タウリンやγ−アミノ酪酸とを併用することにより、単に痛みの抑制、改善のみでなく、ストレスが軽減され、安眠・熟眠ができ、快適な生活ができるという総合的な満足度、体感度が得られ、しかも関節の痛みの抑制、改善効果についても速効性があることを知見し、本発明を完成した。
【0009】
即ち、本発明は、
(1)グルコサミン又はその可食性塩と、タウリン及び/又はγ−アミノ酪酸とを含有することを特徴とする機能性経口組成物、
(2)前記(1)の機能性経口組成物において、乾物基準で、グルコサミン又はその可食性塩100重量部に対し、タウリンを0.01〜100重量部及び/又はγ−アミノ酪酸を0.01〜100重量部の割合で含有する組成物、
(3)前記(1)、(2)の機能性経口組成物において、更に、ムコ多糖、ムコ多糖複合体及びムコ多糖タンパク複合体からなる群から選択される少なくとも1種を、乾物基準でグルコサミン又はその可食性塩100重量部に対し0.5〜1500重量部の割合で含有する組成物、
(4)前記(1)〜(3)の機能性経口組成物において、更に、サリシン含有植物性抽出物を、乾物基準でグルコサミン又はその可食性塩100重量部に対し0.5〜500重量部の割合で含有する組成物、
(5)前記(1)〜(4)の機能性経口組成物において、タウリンが魚介抽出物である組成物、及び
(6)前記(1)〜(5)の機能性組成物において、γ−アミノ酪酸が、米胚芽抽出物又は発酵法により得られたものである組成物、
である。
【0010】
【発明の実施の形態】
本発明の組成物において、その素材の一つであるグルコサミンは、天然アミノ糖の一種であり、海老や蟹の甲羅に含まれているキチン質を酸で加水分解することにより得られ、本発明では常法どおり製造したものを用いることができる。グルコサミンは、通常、塩として得られる場合が多く、本発明ではヒトをはじめとする動物がその適当量を摂取しても安全である塩、すなわち可食性塩であれば特に使用上の制限はない。その好ましい具体例としては、硫酸塩あるいは塩酸塩などが挙げられる。このグルコサミンは、骨、軟骨、皮膚などの組織を構成するムコ多糖の成分であり、軟骨の形成を促進する効果があることから、関節炎などによる関節痛に悩む人々の痛みを軽減し、更に本組成物を継続して摂取することで、関節痛などの症状を根本的に緩和、治療する効果が期待できる。
【0011】
また、タウリン(2−アミノエタンスルホン酸)は、アミノ酸の一種で主に水中に棲む軟体動物(たこ、いかなど)、節足動物(かに、えびなど)、貝類(かき、しじみ、あさり、はまぐり、さざえ、ほたて貝など)、魚(まぐろ、さばなど)などの魚介類に多く含まれていており、これら魚介類からの高濃度抽出物が食品用素材として入手可能であり、本発明では食品レベルで摂取可能なこれら魚介由来のタウリンを好適に使用することができる。このタウリンには、血圧を正常にコントロールしたり、血中のコレステロールを下げる作用があり、更に心臓の機能や肝臓の解毒作用を高めたりする効果が知られている。本発明の組成物において、グルコサミンによる関節痛の抑制、改善効果に加えて、タウリンを併用することにより、関節痛に悩む人々のストレスが軽減され、安眠・熟眠ができ、快適な生活ができ、総合的な満足度、体感度が得られるという効果が期待でき、しかもグルコサミンにタウリンを組み合わせることで、関節痛の抑制、改善効果についての速効性も期待できる。
【0012】
γ−アミノ酪酸は、ギャバ(GABA)と略称される動植物界に広く分布するアミノ酸の一種で、神経の主要な抑制性伝達物質として働き、脳の血流を活発にし、血圧上昇抑制作用、精神を安定させる作用がある。γ−アミノ酪酸は、米胚芽抽出物、または米胚芽、米糠、グルタミン酸から各種発酵法により得られたものが食品用素材として容易に入手可能である。このγ−アミノ酪酸の場合にも、前記タウリンと同様に、グルコサミンによる関節痛の抑制、改善効果に加えて、ストレスが軽減され、安眠・熟眠ができ、快適な生活ができ、総合的な満足度、体感度が得られるという効果が期待でき、更に関節痛の抑制、改善効果についても同様の速効性が期待できる。
【0013】
本発明は、上記のようにグルコサミンにタウリンやγ−アミノ酪酸を併用することで、関節炎などによる関節痛の抑制、改善効果に加えて、総合的な満足度、体感度が得られるのであるが、前記グルコサミンに加えて、グルコサミンと同様に軟骨の形成を促進し、関節痛の抑制、改善効果のあるムコ多糖を組み合わせることで、関節痛の痛みや症状をより効果的に抑制又は改善することができる。また、グルコサミンのかわりに、このムコ多糖を前記タウリンやγ−アミノ酪酸と組み合わせても、前記と同様の効果が期待できる。
【0014】
前記ムコ多糖は、グルコサミノグリカンとも称されており、コンドロイチン硫酸、ケラタン硫酸、デルマッタン硫酸、ヒアルロン酸などの構成成分が知られていて、天然にはこれらのムコ多糖が複合体を形成している。また、このムコ多糖複合体は、更にたんぱく質と複合体を形成し複雑な構造のムコ多糖タンパク複合体として存在している。これらのムコ多糖複合体やムコ多糖タンパク複合体は、動物や微生物に広く分布するものであるが、特に動物(例;サメ、ウシ)の軟骨から抽出されたムコ多糖複合体やムコ多糖タンパク複合体が入手容易である。本発明では、ムコ多糖として、単体のコンドロイチン硫酸を使用してもよいが、コンドロイチン硫酸とケラタン硫酸、デルマッタン硫酸、ヒアルロン酸などとの複合体でも良く、また更に、これらのムコ多糖複合体がタンパク質と複合体を形成しているムコ多糖タンパク複合体も使用することができる。このムコ多糖は、動物の軟骨や粘膜などに多く含まれるものであり、軟骨の形成を促進する効果があることから、本発明の組成物中において、前記グルコサミンと組み合わせることで関節痛の痛みや症状をより効果的に抑制又は改善し、或いはグルコサミンのかわりに用いることで、関節痛の痛みや症状を抑制又は改善する効果を発揮する。
【0015】
更に、本発明の機能性経口組成物には、サリシン含有植物性抽出物を組み合わせてもよい。このサリシン含有植物性抽出物は、セイヨウシロヤナギの樹皮をエタノール水溶液で処理して得られる抽出物に代表されるが、これ以外にもサリシンを含み食用レベルで摂取可能な天然物素材であれば特に限定されない。セイヨウシロヤナギは、ヨーロッパからアジア、北アフリカに分布しており、その樹皮はサリシンを含有する。本発明では、前記セイヨウシロヤナギの樹皮を乾燥し、粉砕したものをエタノール水溶液で抽出し、加熱濃縮したものであって、通常それをさらに乾燥したものが好ましく使用できる。その性状は、独特な香りと味を有する茶色の粉末である。本発明では、サリシンを1重量%以上、好ましくは4重量%以上含有しているものが好ましく、乾物基準で天然物から4倍またはそれ以上に濃縮された抽出物が市販されており、本発明には好ましく使用できる。
【0016】
本発明の組成物においては、乾物基準で、グルコサミン又はその可食性塩100重量部に対し、タウリンは0.01〜100重量部、更には0.1〜20重量部、またγ−アミノ酪酸は0.01〜100重量部、更には0.1〜20重量部の割合で含有することが好ましい。またムコ多糖、ムコ多糖複合体、ムコ多糖タンパク複合体などを含有する場合には、乾物基準でグルコサミン又はその可食性塩100重量部に対し0.5〜1500重量部、更には1〜100重量部の割合で含有することが好ましい。更に、サリシン含有植物性抽出物は、乾物基準でグルコサミン又はその可食性塩100重量部に対し0.5〜500重量部、更には1〜30重量部の割合で含有することが好ましい。
【0017】
また、本発明の経口組成物の一日当たりの摂取量の目安としては、グルコサミン又はその可食性塩を200〜3500mg摂取できる量であり、更にはグルコサミン又はその可食性塩を一日当たり1000〜3500mg摂取できる量とすることが好ましい。
【0018】
本発明の機能性経口組成物の形態は特に限定されるものではなく、粉末状、顆粒状又は錠菓などの各種形態とすることができる。例えば、錠菓の場合には、一日当たり約15錠を摂取することで、上記一日当たりの摂取量が満足できるように、一錠当たりの含量を設定し、セルロースや還元麦芽糖などの結合剤、ショ糖脂肪酸エステルなどの潤沢剤、その他香料などを加えて常法どおり打錠すればよい。また、本発明の組成物は、食品用組成物としてパン類、麺類、菓子類、スープ類、ドリンク類などに混合して摂取するようにしてもよい。
【0019】
本発明の機能性経口組成物は、食品レベルで摂取可能であることから、膝痛などの関節痛に悩む人々が症状の改善を目的として摂取するだけでなく、健常者が摂取すれば、健康な関節の維持に役立てることができる。
【0020】
【実施例】
以下に実施例及び比較例を挙げて本発明を更に詳細に説明するが、本発明はこれらの実施例のみ限定されるものではない。なお、以下の記載中、「%」は「重量%」を意味する。
【0021】
(実施例1)
グルコサミン塩酸塩33.6%及びタウリン(魚介由来:70%タウリン含有)2.0%に、結合剤としてセルロース、滑沢剤としてショ糖脂肪酸エステル、香料及び甘味料を加え、還元麦芽糖で最終的に100%とした。これを造粒して顆粒を得、この顆粒を打錠して錠菓(1錠250mg)を製造した。
【0022】
(実施例2)
タウリンのかわりにγ−アミノ酪酸(発酵生産物:99.0%γ−アミノ酪酸含有)2.0%を用いた以外は、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0023】
(実施例3)
グルコサミン塩酸塩33.6%、実施例1と同じタウリン2.0%及び実施例2と同じγ−アミノ酪酸2.0%と、これに若干の結合剤、滑沢剤、香料及び甘味料を加え、還元麦芽糖で最終的に100%とし、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0024】
(実施例4)
グルコサミン硫酸塩33.6%、タウリン(魚介由来:70%タウリン含有)2.0%、γ−アミノ酪酸(発酵生産物:99.0%γ−アミノ酪酸含有)2.0%、ムコ多糖としてコンドロイチン硫酸(ウシ軟骨由来)10.0%及びサリシン含有植物性抽出物としてセイヨウシロヤナギ樹皮エタノール水溶液抽出物(4倍濃縮)3.2%と、これに若干の結合剤、滑沢剤、香料及び甘味料を加え、還元麦芽糖で最終的に100%とし、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0025】
(実施例5)
グルコサミン塩酸塩33.6%、タウリン(魚介由来:70%タウリン含有)2.0%、ムコ多糖複合体(サメ軟骨由来:ムコ多糖20%含有)10.0%及びサリシン含有植物性抽出物としてセイヨウシロヤナギ樹皮エタノール水溶液抽出物(4倍濃縮)3.2%と、これに若干の結合剤、滑沢剤、香料及び甘味料を加え、還元麦芽糖で最終的に100%とし、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0026】
(比較例1)
グルコサミン塩酸塩33.6%と、これに若干の結合剤、滑沢剤、香料及び甘味料を加え、還元麦芽糖で最終的に100%とし、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0027】
(比較例2)
γ−アミノ酪酸(発酵生産物:99.0%γ−アミノ酪酸含有)2.0%、デキストリン31.6%と、これに若干の結合剤、滑沢剤、香料及び甘味料を加え、還元麦芽糖で最終的に100%とし、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0028】
(比較例3)
タウリン(魚介由来:70%タウリン含有)2.0%に、デキストリン31.6%と、これに若干の結合剤、滑沢剤、香料及び甘味料を加え、還元麦芽糖で最終的に100%とし、実施例1と同様にして錠菓(1錠250mg)を製造した。
【0029】
以上の実施例1〜5及び比較例1〜3の組成物の配合を表1に示す。
【0030】
【表1】
【0031】
(試験例)
実施例1、2、3及び比較例1、2、3で製造した250mg錠菓の6種を用いてアンケート方式にて試験した。試験方法としては、先ず比較例1、2、3で製造した錠菓を各々1日15粒で、各群3名(年齢60〜70歳:関節痛(膝)を有する男女)にて1ヶ月間継続摂取した。その結果を表2に示す。
【0032】
【表2】
【0033】
この結果から明らかなように、比較例1のグルコサミン単独では、若干の痛みの改善を認めたが、関節炎によるストレスの軽減、安眠・熟眠、総合的な満足度が得られず、またγ−アミノ酪酸、タウリンそれぞれ単独の比較例2、3では、関節炎による関節の痛みの軽減、関節炎によるストレスの軽減、安眠・熟眠、総合的な満足度のいずれも得られなかった。
【0034】
次ぎに、実施例1、2、3で製造した錠菓についても同様に試験した結果を表2に示す。
【0035】
【表3】
【0036】
表3の結果に示すように、グルコサミンとタウリン又はγ−アミノ酪酸を組み合わせると、関節炎による関節の痛みの軽減の効果がより体感できるようになると同時に、関節炎によるストレスの軽減、安眠・熟眠、そして総合的な満足度が得られた。しかも、摂取1週間後には効果が表れており、比較例に比べて速効性があることも明らかである。更に、タウリンとγ−アミノ酪酸とを併用した場合により効果が認められた。
【0037】
【発明の効果】
以上のように、本発明の機能性経口組成物は、軟骨を形成する効果があり、健康な関節の維持に有効なグルコサミン又はムコ多糖により関節炎等に伴う関節痛の抑制、改善効果に加え、タウリン又はγ−アミノ酪酸により関節痛に悩む人々の総合的な満足度、体感度を向上させることができ、しかも関節痛の抑制、改善効果にも速効性があり、関節痛に悩む人々の日常生活を快適なものに改善することができる。また、この機能性経口組成物は、その全てを天然素材から調製することができ、食品レベルで日常的に手軽に摂取することができることから、本組成物を継続して摂取すれば、グルコサミン又はムコ多糖により軟骨形成も促進され、関節炎などの根本的治療にも貢献しうるものである。
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a functional oral composition that can be taken in a food form and has a function of suppressing or improving pain associated with arthritis.
[0002]
[Prior art]
In the modern society, with the progress of aging, the number of people who are suffering from joint pain at the same time as adult diseases is increasing rapidly. In this joint pain, the cartilage acting as a cushion for the joint is consumed and the bones come into contact with each other, so that the joint feels pain. Therefore, as a method for improving and treating joint pain, a method of replenishing glucosamine and chondroitin sulfate, which are components of joints and cartilage, is widely used.
[0003]
Glucosamine is a substance obtained from chitin contained in the shells of salmon and shrimp, and is a component of mucopolysaccharides that form tissues such as bone, cartilage, and skin, and is used for osteoarthritis mainly in the United States and Europe. The therapeutic effect has attracted attention, and many clinical trials have been reported. On the other hand, the chondroitin sulfate is a mucopolysaccharide that is contained in a large amount in the cartilage and mucous membranes of animals and plants, and has a function of improving the shock absorption and durability of the cartilage.
[0004]
Glucosamine and chondroitin sulfate are known to be effective materials for maintaining healthy joints by promoting cartilage formation through separate pathways, and it has already been disclosed that excellent therapeutic effects can be obtained especially when both are used in combination. (For example, refer to Patent Document 1). In addition, glucosamine and chondroitin sulfate contain a salicin-containing plant extract (extract of white willow) that can be ingested at the food level, suppresses or improves pain such as arthritis, and treats arthritis A food composition that leads in the direction is also disclosed (see Patent Document 2).
[0005]
[Patent Document 1]
Japanese Patent No. 2971579 [Patent Document 2]
JP-A-2001-314173 [0006]
[Problems to be solved by the invention]
However, the conventional improvement and treatment methods for arthritis as described above are focused on the repair of worn cartilage and the reduction of pain by the chondrogenic function of mucopolysaccharides such as glucosamine or chondroitin sulfate. It was not sufficient in terms of overall satisfaction and sensitivity to people suffering from arthritis, and it lacked rapid efficacy. The total satisfaction and body sensitivity here mean that in addition to the reduction of joint pain due to arthritis, the stress due to arthritis is reduced, and a comfortable sleep can be achieved.
[0007]
In view of the problems in the conventional methods for dealing with arthralgia such as arthritis, the present invention not only repairs the worn cartilage and reduces pain, but also reduces stress due to arthralgia, It is intended to provide a functional oral composition that is capable of taking a deep sleep and having a comfortable life, providing overall satisfaction and body sensitivity, being fast-acting and ingestible as a food.
[0008]
[Means for Solving the Problems]
The present inventor has conducted research on methods that can give people who suffer from joint pain not only relieve joint pain but also obtain overall satisfaction and body sensitivity. By using mucopolysaccharides such as glucosamine and chondroitin sulfate, which are known to suppress or relieve pain, in combination with taurine and γ-aminobutyric acid, not only pain is suppressed and improved, but stress is reduced, The present inventors completed the present invention by discovering that the overall satisfaction and body sensitivity of being able to sleep comfortably and deeply and having a comfortable life were obtained, and that the effect of suppressing and improving joint pain was also rapid.
[0009]
That is, the present invention
(1) A functional oral composition comprising glucosamine or an edible salt thereof, taurine and / or γ-aminobutyric acid,
(2) In the functional oral composition of the above (1), 0.01 to 100 parts by weight of taurine and / or γ-aminobutyric acid is 0.1% with respect to 100 parts by weight of glucosamine or an edible salt thereof on a dry matter basis. A composition containing at a ratio of 01 to 100 parts by weight,
(3) In the functional oral composition of (1) and (2), at least one selected from the group consisting of a mucopolysaccharide, a mucopolysaccharide complex, and a mucopolysaccharide protein complex is further added to glucosamine on a dry matter basis. Or a composition containing 0.5 to 1500 parts by weight with respect to 100 parts by weight of the edible salt,
(4) In the functional oral composition of (1) to (3), the salicin-containing plant extract is further added in an amount of 0.5 to 500 parts by weight based on 100 parts by weight of glucosamine or edible salt based on dry matter. A composition containing at a ratio of
(5) In the functional oral composition of (1) to (4), taurine is a seafood extract, and (6) in the functional composition of (1) to (5), γ- A composition in which aminobutyric acid is obtained by a rice germ extract or fermentation method,
It is.
[0010]
DETAILED DESCRIPTION OF THE INVENTION
In the composition of the present invention, glucosamine, which is one of the raw materials, is a kind of natural amino sugar, and is obtained by hydrolyzing chitin contained in shrimp and shark shells with an acid. Then, what was manufactured as usual can be used. In general, glucosamine is often obtained as a salt, and in the present invention, there is no particular limitation in use as long as it is a salt that is safe even if an animal including human beings takes an appropriate amount thereof, that is, an edible salt. . Preferable specific examples thereof include sulfate or hydrochloride. This glucosamine is a component of mucopolysaccharide that constitutes tissues such as bone, cartilage and skin, and has the effect of promoting the formation of cartilage, thus reducing the pain of people suffering from joint pain due to arthritis, etc. By continuously ingesting the composition, it is expected to have an effect of fundamentally relieving and treating symptoms such as joint pain.
[0011]
Taurine (2-aminoethanesulfonic acid) is a kind of amino acid, mainly mollusks (octopus, squid, etc.), arthropods (crab, shrimp, etc.), shellfish (oysters, shijimi, clams, It is abundant in seafood such as fish, fish and shellfish, and fish (tuna, mackerel, etc.), and high-concentration extracts from these seafood are available as food materials. These seafood-derived taurines that can be ingested at the food level can be suitably used. This taurine has an effect of controlling blood pressure normally, lowering cholesterol in blood, and further enhancing the function of heart and liver detoxification. In the composition of the present invention, in addition to the suppression and improvement effects of joint pain by glucosamine, by using taurine in combination, the stress of people suffering from joint pain is reduced, and a comfortable sleep can be achieved. Combined with glucosamine and taurine, it can be expected to be effective for suppressing joint pain and improving effects.
[0012]
γ-Aminobutyric acid is a kind of amino acid widely distributed in the animal and plant kingdom, which is abbreviated as GABA. It acts as a major inhibitory transmitter of nerves, activates blood flow in the brain, suppresses blood pressure rise, Has the effect of stabilizing. γ-aminobutyric acid can be easily obtained as a food material from rice germ extract or rice germ, rice bran, and glutamic acid obtained by various fermentation methods. In the case of this γ-aminobutyric acid as well as taurine, in addition to the suppression and improvement effects of joint pain by glucosamine, stress is reduced, and sleep and deep sleep can be achieved. The effect that the sensitivity and body sensitivity can be obtained can be expected, and the same immediate effect can be expected for the suppression and improvement effects of joint pain.
[0013]
In the present invention, by using taurine or γ-aminobutyric acid in combination with glucosamine as described above, overall satisfaction and body sensitivity can be obtained in addition to the suppression and improvement effects of arthritis and the like. In addition to the above glucosamine, it promotes the formation of cartilage in the same manner as glucosamine, and suppresses or improves the pain and symptoms of joint pain more effectively by combining mucopolysaccharides that suppress and improve joint pain. Can do. Further, when this mucopolysaccharide is combined with the taurine or γ-aminobutyric acid instead of glucosamine, the same effect as described above can be expected.
[0014]
The mucopolysaccharide is also called a glucosaminoglycan, and its constituent components such as chondroitin sulfate, keratan sulfate, dermattan sulfate, and hyaluronic acid are known. Naturally, these mucopolysaccharides form a complex. Yes. Further, this mucopolysaccharide complex exists as a mucopolysaccharide protein complex having a complex structure by forming a complex with a protein. These mucopolysaccharide complexes and mucopolysaccharide protein complexes are widely distributed in animals and microorganisms. In particular, mucopolysaccharide complexes and mucopolysaccharide protein complexes extracted from the cartilage of animals (eg, sharks and cattle). The body is easy to obtain. In the present invention, a single chondroitin sulfate may be used as the mucopolysaccharide, but a complex of chondroitin sulfate and keratan sulfate, dermattan sulfate, hyaluronic acid, or the like may be used. Furthermore, these mucopolysaccharide conjugates are protein. A mucopolysaccharide protein complex that forms a complex with can also be used. This mucopolysaccharide is abundant in animal cartilage and mucous membranes, and has the effect of promoting cartilage formation. Therefore, in the composition of the present invention, joint pain and By suppressing or improving the symptoms more effectively, or by using instead of glucosamine, the effect of suppressing or improving the pain and symptoms of joint pain is exhibited.
[0015]
Furthermore, you may combine a salicin containing plant extract with the functional oral composition of this invention. This salicin-containing plant extract is typified by an extract obtained by treating bark of white willow with an aqueous ethanol solution, but in addition to this, it is particularly natural if it is a natural product material that contains salicin and can be consumed at the edible level. It is not limited. The willow tree is distributed from Europe to Asia and North Africa, and its bark contains salicin. In the present invention, the dried white willow bark is dried and pulverized, extracted with an aqueous ethanol solution, concentrated by heating, and usually dried further. Its properties are a brown powder with a unique aroma and taste. In the present invention, those containing 1% by weight or more, preferably 4% by weight or more of salicin are preferred, and extracts that are concentrated four times or more from natural products on a dry matter basis are commercially available. Can be preferably used.
[0016]
In the composition of the present invention, taurine is 0.01 to 100 parts by weight, further 0.1 to 20 parts by weight, and γ-aminobutyric acid is 100 parts by weight of glucosamine or its edible salt on a dry matter basis. The content is preferably 0.01 to 100 parts by weight, more preferably 0.1 to 20 parts by weight. In the case of containing mucopolysaccharide, mucopolysaccharide complex, mucopolysaccharide protein complex, etc., 0.5 to 1500 parts by weight, further 1 to 100 parts by weight with respect to 100 parts by weight of glucosamine or its edible salt on a dry matter basis. It is preferable to contain by the ratio of a part. Further, the salicin-containing plant extract is preferably contained in a proportion of 0.5 to 500 parts by weight, more preferably 1 to 30 parts by weight, based on 100 parts by weight of glucosamine or edible salt on a dry matter basis.
[0017]
Moreover, as a standard of the intake amount per day of the oral composition of the present invention, it is an amount capable of ingesting 200 to 3500 mg of glucosamine or an edible salt thereof, and further ingesting 1000 to 3500 mg of glucosamine or an edible salt thereof per day. It is preferable that the amount be as large as possible.
[0018]
The form of the functional oral composition of the present invention is not particularly limited, and can be various forms such as powder, granules, or tablet confectionery. For example, in the case of tablet confectionery, by taking about 15 tablets per day, the content per tablet is set so that the above-mentioned daily intake can be satisfied, binders such as cellulose and reduced maltose, A lubricant such as sucrose fatty acid ester and other flavoring agents may be added and tableted as usual. Further, the composition of the present invention may be ingested as a food composition mixed with breads, noodles, confectionery, soups, drinks and the like.
[0019]
Since the functional oral composition of the present invention can be taken at the food level, people suffering from joint pain such as knee pain not only take it for the purpose of improving symptoms, but if healthy people take it, Can be used to maintain a healthy joint.
[0020]
【Example】
EXAMPLES The present invention will be described in more detail with reference to examples and comparative examples below, but the present invention is not limited only to these examples. In the following description, “%” means “% by weight”.
[0021]
(Example 1)
Glucosamine hydrochloride 33.6% and taurine (derived from seafood: containing 70% taurine) 2.0% cellulose as binder, sucrose fatty acid ester, flavor and sweetener as lubricant, and finally with reduced maltose To 100%. This was granulated to obtain granules, and the granules were tableted to produce tablet confectionery (1 tablet 250 mg).
[0022]
(Example 2)
A tablet confection (1 tablet 250 mg) was produced in the same manner as in Example 1 except that 2.0% of γ-aminobutyric acid (fermented product: 99.0% γ-aminobutyric acid) was used instead of taurine. .
[0023]
(Example 3)
Glucosamine hydrochloride 33.6%, the same taurine 2.0% as in Example 1, and the same γ-aminobutyric acid 2.0% as in Example 2, plus some binders, lubricants, flavors and sweeteners. In addition, reduced maltose was used to finally make 100%, and tablet confectionery (1 tablet 250 mg) was produced in the same manner as in Example 1.
[0024]
Example 4
Glucosamine sulfate 33.6%, taurine (derived from seafood: containing 70% taurine) 2.0%, γ-aminobutyric acid (fermented product: containing 99.0% γ-aminobutyric acid) 2.0%, mucopolysaccharide Chondroitin sulfate (derived from bovine cartilage) 10.0% and salicin-containing plant extract, white willow bark ethanol aqueous solution extract (concentrated 4 times) 3.2%, and some binders, lubricants, fragrances and A sweetener was added, and the final maltose was made 100%, and a tablet confection (1 tablet 250 mg) was produced in the same manner as in Example 1.
[0025]
(Example 5)
As a plant extract containing 33.6% glucosamine hydrochloride, taurine (derived from seafood: containing 70% taurine) 2.0%, mucopolysaccharide complex (derived from shark cartilage: containing 20% mucopolysaccharide) 10.0% and salicin A white willow bark ethanol aqueous solution extract (concentrated 4 times) 3.2%, and some binders, lubricants, fragrances and sweeteners were added thereto, and finally reduced to 100% with reduced maltose. Similarly, tablet confectionery (1 tablet 250 mg) was produced.
[0026]
(Comparative Example 1)
Glucosamine hydrochloride 33.6% and some binders, lubricants, fragrances and sweeteners were added thereto, and finally reduced to 100% with reduced maltose. ) Was manufactured.
[0027]
(Comparative Example 2)
γ-aminobutyric acid (fermented product: containing 99.0% γ-aminobutyric acid) 2.0%, dextrin 31.6%, and some binders, lubricants, flavors and sweeteners added thereto, and reduced. Tablets (1 tablet 250 mg) were produced in the same manner as in Example 1 with 100% maltose.
[0028]
(Comparative Example 3)
Taurine (derived from seafood: 70% taurine contained) 2.0%, dextrin 31.6%, and some binders, lubricants, flavors and sweeteners added to it, and finally reduced to 100% with reduced maltose In the same manner as in Example 1, tablet confectionery (1 tablet 250 mg) was produced.
[0029]
Table 1 shows the composition of the compositions of Examples 1 to 5 and Comparative Examples 1 to 3 described above.
[0030]
[Table 1]
[0031]
(Test example)
The six types of 250 mg tablet confections produced in Examples 1, 2, and 3 and Comparative Examples 1, 2, and 3 were used and tested in a questionnaire system. As a test method, the tablet confections produced in Comparative Examples 1, 2 and 3 were each 15 tablets per day for 3 months in each group (age 60-70 years: men and women with joint pain (knee)) for 1 month. Ingested continuously. The results are shown in Table 2.
[0032]
[Table 2]
[0033]
As is apparent from these results, the glucosamine of Comparative Example 1 alone showed some improvement in pain, but the reduction of stress due to arthritis, restful sleep / deep sleep, overall satisfaction could not be obtained, and γ-amino In Comparative Examples 2 and 3 each having only butyric acid and taurine, none of the reduction of joint pain due to arthritis, the reduction of stress due to arthritis, sleep / deep sleep, and overall satisfaction were obtained.
[0034]
Next, Table 2 shows the results of a similar test for the tablet confections produced in Examples 1, 2, and 3.
[0035]
[Table 3]
[0036]
As shown in the results of Table 3, when glucosamine and taurine or γ-aminobutyric acid are combined, the effect of reducing joint pain due to arthritis can be more experienced, while reducing stress due to arthritis, Overall satisfaction was obtained. Moreover, the effect appears one week after ingestion, and it is clear that the effect is faster than the comparative example. Furthermore, the effect was recognized when taurine and γ-aminobutyric acid were used in combination.
[0037]
【The invention's effect】
As described above, the functional oral composition of the present invention has an effect of forming cartilage, and in addition to the effect of suppressing and improving joint pain associated with arthritis and the like with glucosamine or mucopolysaccharide effective for maintaining healthy joints, Taurine or γ-aminobutyric acid can improve the overall satisfaction and sensitivity of people suffering from joint pain, and it is effective in suppressing and improving joint pain. You can improve your life comfortably. In addition, since this functional oral composition can be prepared entirely from natural materials and can be easily taken on a daily basis at the food level, if this composition is continuously taken, glucosamine or Mucopolysaccharide also promotes cartilage formation and can contribute to fundamental treatment such as arthritis.

Claims (6)

グルコサミン又はその可食性塩と、タウリン及び/又はγ−アミノ酪酸とを含有することを特徴とする機能性経口組成物。A functional oral composition comprising glucosamine or an edible salt thereof and taurine and / or γ-aminobutyric acid. 乾物基準で、グルコサミン又はその可食性塩100重量部に対し、タウリンを0.01〜100重量部及び/又はγ−アミノ酪酸を0.01〜100重量部の割合で含有する請求項1記載の機能性経口組成物。The content of taurine is 0.01 to 100 parts by weight and / or γ-aminobutyric acid in a proportion of 0.01 to 100 parts by weight with respect to 100 parts by weight of glucosamine or an edible salt thereof on a dry matter basis. Functional oral composition. 更に、ムコ多糖、ムコ多糖複合体及びムコ多糖タンパク複合体からなる群から選択される少なくとも1種を、乾物基準でグルコサミン又はその可食性塩100重量部に対し0.5〜1500重量部の割合で含有する請求項1又は2に記載の機能性経口組成物。Further, at least one selected from the group consisting of mucopolysaccharide, mucopolysaccharide complex and mucopolysaccharide protein complex is a ratio of 0.5 to 1500 parts by weight with respect to 100 parts by weight of glucosamine or edible salt based on dry matter The functional oral composition of Claim 1 or 2 contained in. 更に、サリシン含有植物性抽出物を、乾物基準でグルコサミン又はその可食性塩100重量部に対し0.5〜500重量部の割合で含有する請求項1〜3のいずれかに記載の機能性経口組成物。Furthermore, the functional oral in any one of Claims 1-3 which contain a salicin containing plant extract in the ratio of 0.5-500 weight part with respect to 100 weight part of glucosamine or its edible salt on a dry matter basis. Composition. タウリンが魚介抽出物である請求項1〜4のいずれかに記載の機能性経口組成物。The functional oral composition according to any one of claims 1 to 4, wherein taurine is a seafood extract. γ−アミノ酪酸が、米胚芽抽出物又は発酵法により得られたものである請求項1〜5のいずれかに記載の機能性経口組成物。The functional oral composition according to any one of claims 1 to 5, wherein γ-aminobutyric acid is obtained by a rice germ extract or a fermentation method.
JP2002361581A 2002-12-13 2002-12-13 Functional composition for oral administration Pending JP2004189685A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002361581A JP2004189685A (en) 2002-12-13 2002-12-13 Functional composition for oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002361581A JP2004189685A (en) 2002-12-13 2002-12-13 Functional composition for oral administration

Publications (1)

Publication Number Publication Date
JP2004189685A true JP2004189685A (en) 2004-07-08

Family

ID=32760252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002361581A Pending JP2004189685A (en) 2002-12-13 2002-12-13 Functional composition for oral administration

Country Status (1)

Country Link
JP (1) JP2004189685A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036644A (en) * 2004-07-22 2006-02-09 Yaizu Suisankagaku Industry Co Ltd Manufacturing method of glucosamine granule, glucosamine granule and glucosamine tablet
JP2008024623A (en) * 2006-07-20 2008-02-07 Taisho Pharmaceut Co Ltd Oral composition
JP2015034140A (en) * 2013-08-08 2015-02-19 サンスター株式会社 Anti-obesity agent
CN104688554A (en) * 2015-01-30 2015-06-10 柳州两面针股份有限公司 Application of saligenin in preparation of mouth care healthcare product
WO2016068317A1 (en) * 2014-10-31 2016-05-06 小林製薬株式会社 Oral composition
CN108714208A (en) * 2018-06-21 2018-10-30 北京斯利安药业有限公司 Composition, preparation method, using and relieve stress, improve sleep product

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036644A (en) * 2004-07-22 2006-02-09 Yaizu Suisankagaku Industry Co Ltd Manufacturing method of glucosamine granule, glucosamine granule and glucosamine tablet
JP2008024623A (en) * 2006-07-20 2008-02-07 Taisho Pharmaceut Co Ltd Oral composition
JP2015034140A (en) * 2013-08-08 2015-02-19 サンスター株式会社 Anti-obesity agent
WO2016068317A1 (en) * 2014-10-31 2016-05-06 小林製薬株式会社 Oral composition
JP2016088870A (en) * 2014-10-31 2016-05-23 小林製薬株式会社 Oral composition
CN104688554A (en) * 2015-01-30 2015-06-10 柳州两面针股份有限公司 Application of saligenin in preparation of mouth care healthcare product
CN108714208A (en) * 2018-06-21 2018-10-30 北京斯利安药业有限公司 Composition, preparation method, using and relieve stress, improve sleep product

Similar Documents

Publication Publication Date Title
CN101194729A (en) Chopped meat made from multiple meats, production method and uses thereof
KR20100121035A (en) The way to make yaksun food, the food good for health
JP4818177B2 (en) Bone and muscle enhancement promoting composition for elderly
CN105212220A (en) A kind of composite nutrition powder and preparation method thereof
KR20100016876A (en) A mixed grain for diet and glycosuria
JP2006006156A (en) Liver function-enhancing health food
KR100585970B1 (en) Method for rearing duck and meat therefor
CN102273581A (en) Compound sweetener with high sweetness
KR101716766B1 (en) How to breed crickets and food composition comprising the crickets
JP2004189685A (en) Functional composition for oral administration
JP2000166467A (en) Health food containing fermented milk product and herbs
JP4484254B2 (en) Amino acid composition
JP2013138632A (en) Food composition
JPH0937711A (en) Health food
KR101253342B1 (en) Composition Vitamin With Dry Laver
KR20180056199A (en) Manufacturing method of gum for diet containing Moringa Oleifera extract
KR101092749B1 (en) Soybean paste containing a sulfur duck and production method thereof
JP4380117B2 (en) Tablet containing soybean 7S protein
EP1239742B1 (en) Honey based food product for relief of gastroesophageal reflux disease and stomach complaints and compressed product comprising said composition
JP2009034017A (en) Diet food
KR101046787B1 (en) Hangover drink composition
KR20060038969A (en) Processed foods with the theme of seaweed (whole grain powder) and kelp
KR101122427B1 (en) The frog soup
JP2001314173A (en) Composition for food
JP4163801B2 (en) Alcohol metabolism promoting agent

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070306